Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch LLP | PRODUCT CODE: 1183688

Cover Image

PUBLISHER: 360iResearch LLP | PRODUCT CODE: 1183688

Omics-Based Clinical Trials Market Research Report by Phase (Phase I, Phase II, and Phase III), Study Design, Indication, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

PUBLISHED:
PAGES: 225 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Online Access - 1 Year (Single User License)
USD 3949
PDF & Excel + Online Access - 1 Year (Single User License)
USD 4949
PDF & Excel + Online Access - 1 Year (Up to 5 User License)
USD 5949
PDF & Excel + Online Access - 1 Year (Site License)
USD 6949
PDF & Excel + Online Access - 1 Year (Enterprise User License)
USD 8949

Add to Cart

The Global Omics-Based Clinical Trials Market size was estimated at USD 27.91 billion in 2022 and expected to reach USD 30.10 billion in 2023, projecting growth at a CAGR of 8.32% to reach USD 52.92 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Omics-Based Clinical Trials Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people's lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Omics-Based Clinical Trials Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Omics-Based Clinical Trials Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Omics-Based Clinical Trials Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Omics-Based Clinical Trials Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Phase, the market is studied across Phase I, Phase II, Phase III, and Phase IV.

Based on Study Design, the market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.

Based on Indication, the market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Omics-Based Clinical Trials Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Omics-Based Clinical Trials Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Omics-Based Clinical Trials Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Omics-Based Clinical Trials Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor's strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Omics-Based Clinical Trials Market, including Complete Omics, Inc., Covance Inc., Danaher Corporation, Eli Lilly and Company, ICON Plc, Laboratory Corporation of America Holdings, Merck & Co. Inc., Mission Bio, Inc., NeoGenomics Laboratories, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer, Inc., Rebus Biosystems, Inc., SGS SA, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Omics-Based Clinical Trials Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Omics-Based Clinical Trials Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Omics-Based Clinical Trials Market?

4. What is the competitive strategic window for opportunities in the Global Omics-Based Clinical Trials Market?

5. What are the technology trends and regulatory frameworks in the Global Omics-Based Clinical Trials Market?

6. What is the market share of the leading vendors in the Global Omics-Based Clinical Trials Market?

7. What modes and strategic moves are considered suitable for entering the Global Omics-Based Clinical Trials Market?

Product Code: MRR-3A2E844FD400

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
      • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
      • 5.1.1.3. Growing focus on personalized medicine and oncology trials
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of omics-based clinical trials products
    • 5.1.3. Opportunities
      • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
      • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
    • 5.1.4. Challenges
      • 5.1.4.1. Issues relating to effective data analysis
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Cumulative Impact of Russia-Ukraine Conflict
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Threat of Substitutes
    • 5.5.4. Threat of Substitutes
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework
  • 5.8. Client Customization

6. Omics-Based Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. CNS Diseases
  • 8.4. Genetic Diseases
  • 8.5. Immunology
  • 8.6. Oncology
  • 8.7. Respiratory Diseases
  • 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis, By Key Player
  • 12.3. Market Share Analysis, By Key Player
  • 12.4. Product Portfolio Analysis, By Key Player
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Complete Omics, Inc.
  • 13.2. Covance Inc.
  • 13.3. Danaher Corporation
  • 13.4. Eli Lilly and Company
  • 13.5. ICON Plc
  • 13.6. Laboratory Corporation of America Holdings
  • 13.7. Merck & Co. Inc.
  • 13.8. Mission Bio, Inc.
  • 13.9. NeoGenomics Laboratories, Inc.
  • 13.10. Novo Nordisk A/S
  • 13.11. Parexel International Corporation
  • 13.12. Pfizer, Inc.
  • 13.13. Rebus Biosystems, Inc.
  • 13.14. SGS SA
  • 13.15. Thermo Fisher Scientific, Inc.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
Product Code: MRR-3A2E844FD400

LIST OF FIGURES

  • FIGURE 1. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
  • FIGURE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET DYNAMICS
  • FIGURE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 12. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
  • FIGURE 13. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY PHASE, 2030
  • FIGURE 15. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
  • FIGURE 16. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
  • FIGURE 17. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
  • FIGURE 18. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
  • FIGURE 19. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2030 (%)
  • FIGURE 20. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY STUDY DESIGN, 2030
  • FIGURE 22. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, 2018-2030 (USD MILLION)
  • FIGURE 23. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, 2018-2030 (USD MILLION)
  • FIGURE 24. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, 2018-2030 (USD MILLION)
  • FIGURE 25. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 26. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 27. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
  • FIGURE 28. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • FIGURE 29. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, 2018-2030 (USD MILLION)
  • FIGURE 30. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, 2018-2030 (USD MILLION)
  • FIGURE 31. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • FIGURE 32. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • FIGURE 33. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
  • FIGURE 34. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, 2018-2030 (USD MILLION)
  • FIGURE 35. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 36. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 37. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 38. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 39. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 40. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 41. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 42. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 43. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 44. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 45. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 46. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
  • FIGURE 47. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 48. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 49. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 50. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 51. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 52. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 53. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 54. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 55. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 56. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 57. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 58. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 59. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 60. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 61. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 62. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 64. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 65. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 66. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 67. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 68. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 69. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 70. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 71. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 72. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 73. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 74. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 75. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 76. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 77. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 78. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 79. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 80. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 81. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 82. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 83. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 84. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 85. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 86. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 87. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 88. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX, 2022
  • FIGURE 89. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
  • FIGURE 90. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

LIST OF TABLES

  • TABLE 1. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 180. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 184. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 185. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 188. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 189. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 190. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 196. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 197. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 198. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 200. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 202. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 204. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 205. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 206. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 208. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 209. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 210. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 212. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 213. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 214. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 216. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 217. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 218. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
  • TABLE 220. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
  • TABLE 221. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
  • TABLE 222. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET RANKING, BY KEY PLAYER, 2022
  • TABLE 223. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 224. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
  • TABLE 225. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET MERGER & ACQUISITION
  • TABLE 226. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 227. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 228. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET INVESTMENT & FUNDING
  • TABLE 229. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET AWARD, RECOGNITION, & EXPANSION
  • TABLE 230. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!